Fibrous Dysplasia of Bone
8
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Fibrous Dysplasia: An Epidemiological and Correlational Study of Multimodal Data
PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study
Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE
Epigenetic Regulation in Fibrous Dysplasia of Bone: mirDYS Study.
Hepato-pancreato-biliary Abnormalities in Fibrous Dysplasia of Bone/McCune Albright Syndrome
Effectiveness of Medical Management of Fibrous Dysplasia of Bone.
Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone